Skip to content
HW210605 PREDiCT Tumour Models London logo

14 - 16 December, 2021
Digital Event, GMT

  • Home
  • About
    • About Event
    • About the PREDiCT Series
    • Content Hub
    • Testimonials
    • About Digital
    • FAQs
  • Programme
    • Full Event Guide
    • Speakers
    • Pre-Conference Workshop Day
    • Agenda
      • Day One
      • Day Two
  • Partnerships
    • Partnership Opportunities
    • Partners
    • Media Partners
    • PREDiCT Series Prospectus
  • Take Part
    • Register Interest
    • Contact us

Mi-mAbs

By digitalsystems | 31st July 2019

Mi-mAbs is an innovative integrated immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory diseases. Open to the best targets of academic and industrial research, MI-mAbs determines their expression profile, generates antibodies and validates them.

MI-mAbs, a multi-disciplinary team, involving experts in hybridoma, in molecular biology, biochemistry, immunochemistry , anatomopathology and in vitro/in vivo immunopharmacology has an objective to be the 1st integrated platform that generates and validates therapeutic antibodies in Cancerology and Inflammation. MI-mAbs contracts with research institutions, public technology transfer offices, or biotech companies

www.mimabs.org

OUR CONTACT DETAILS

T: +44 (0)20 3141 8700
E: info@hansonwade.com

VENUE DETAILS

Digital Event

ABOUT US

Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.

SEARCH

ORGANISED BY

HansonWade Logo

Terms & Conditions

Privacy Policy

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.